New device aims to improve breast reconstruction safety
NCT ID NCT06556654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medical device designed to reinforce breast reconstruction surgery after mastectomy. About 180 women having their first breast reconstruction will be enrolled, with some receiving the device and others having standard surgery without it. The goal is to see if the device reduces complications like hospital readmission or repeat surgery, and improves chest well-being.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Female subjects ≥ 22 years of age. 2. First-time breast reconstruction post-mastectomy for target breast(s). 3. Scheduled to undergo unilateral or bilateral mastectomy with immediate, two-stage, implant-based, subpectoral or prepectoral breast reconstruction after mastectomy. 4. Mastectomy performed to address breast cancer or for cancer prophylaxis. 5. An informed consent form is signed by Subject or Legally Authorized Representative (LAR). 6. Subject is capable of following protocol procedures and complying with follow-up visit requirements Exclusion Criteria: Baseline Exclusion Criteria 1. Subject has had a revision(s) in the target breast(s) following complications of breast augmentation, mastopexy (breast lift), or breast reduction. 2. Subject has undergone previous radiation therapy to the reconstruction site or chest wall. 3. Subject has had chemotherapy within 3 weeks prior to the index procedure. 4. Subject has been treated for a systemic infection or local infection at the surgical site within 30 days prior to index procedure. 5. Subject has a current or previous diagnosis of Methicillin-resistant Staphylococcus aureus (MRSA). 6. Subject has a BMI \> 35. 7. Subject has a known diagnosis of diabetes with a HbA1c \> 7.0mmol/L within 30 days of the Index procedure (i.e., TE placement). 8. Subject was a current or former tobacco/nicotine user, within 90 days prior to Index Surgery (i.e., TE placement). 9. Subject is currently taking medication (e.g., systemic steroid), which in the investigator's opinion, may increase the risk of local complications of breast reconstruction. 10. Subject has other medical, social, or psychological conditions which could interfere with provision of informed consent, completion of tests, therapy, or follow-up. 11. Subject is currently participating in or planning to participate in another investigational drug, biologic or medical device study that may interfere with compliance of TBR 22-07 study requirements or may confound TBR 22-07 study data/outcomes. 12. Subject requires a surgical technique requiring flap (autologous tissue). 13. Subject is pregnant or lactating at the time of the index procedure (i.e., TE placement) or is planning to become pregnant prior to the Exchange procedure. Intraoperative Index Procedure Exclusion 14. Based on investigator's opinion, subject has unsuitable tissue integrity for immediate 2-stage breast reconstruction or is no longer a candidate to receive the TRBR Device (will be recorded as a screen failure). 15. Subject receives an Acellular Dermal Matrix (ADM) or mesh that is not the TRBR Device in the target breast(s)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
20 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
BR Hope LLC
RECRUITINGWichita, Kansas, 67206, United States
-
Cedars-Sinai Plastic and Reconstruction Surgery
NOT_YET_RECRUITINGLos Angeles, California, 90048, United States
-
Corewell Health Research Institute
RECRUITINGGrand Rapids, Michigan, 49503, United States
-
Endeavor Health (Northshore University HealthSystem Research Institute)
RECRUITINGEvanston, Illinois, 60201-3137, United States
-
Mayo Clinic Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
-
Mayo Clinic Florida
RECRUITINGJacksonville, Florida, 32224, United States
-
Northwestern University
RECRUITINGEvanston, Illinois, 60208, United States
-
Riverside University Health System-Medical Center
RECRUITINGMoreno Valley, California, 92555, United States
-
The Board of Regents of the University of Nebraska
RECRUITINGOmaha, Nebraska, 68198-5331, United States
-
The Board of Regents of the University of Wisconsin System
RECRUITINGMadison, Wisconsin, 53715, United States
-
The Cleveland Clinic Foundation
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
-
The Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
-
The Joan and Sanford I. Weill Medical College of Cornell University
RECRUITINGNew York, New York, 10065, United States
-
The Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21205, United States
-
The Medical College of Wisconsin, Inc.
NOT_YET_RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
The Regents of the University of California
NOT_YET_RECRUITINGIrvine, California, 92697-7600, United States
-
The University of Washington Medical Center
RECRUITINGSeattle, Washington, 98195, United States
-
University of Arizona
RECRUITINGTucson, Arizona, 85724, United States
-
University of Mississippi
RECRUITINGJackson, Mississippi, 39216, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?